Hospital del Mar Research Institute

Name

Hospital del Mar Research Institute

Legal name

Institut Municipal d'Investigació Mèdica

Website

https://researchmar.net

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

Keywords

• Biomedical research services
• Translational clinical research
• Cancer research programs
• Neuroscience research
• Scientific technical platforms

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Distribution channels3 records

Marketing channels3 records

Core offering

Hospital del Mar Research Institute is a public biomedical research institute operating five research programmes (Cancer, Epidemiology and Public Health, Biomedical Informatics, Neurosciences, and Translational Clinical Research) that conduct clinical and translational research. It also operates a Scientific & Technical Services (SCT) platform offering specialized services including MARGenomics, MARBiobanc, MARData, MARMetabolomics, a Clinical Research Unit for Phase I trials, and enzyme immunoassay and cryopreservation services. These services are made available to Hospital del Mar, other Parc de Salut Mar centres, PRBB institutions, and external public institutions and private companies through formal agreements.

Product overview

Hospital del Mar Research Institute operates as a research institute offering a platform of Scientific & Technical Services (SCT) providing scientific and infrastructural support to researchers. The services include MARGenomics (genomic studies), MARBiobanc (biological sample collections), MARData (data science services), MARMetabolomics (metabolomics platform), Clinical Research Unit (Phase I trials), Enzyme Immuno Assay service, and Internal Services with Cryopreservation. The institute also conducts research through dedicated programs in Cancer, Neurosciences, Epidemiology and Public Health, Biomedical Informatics, Translational Clinical Research, and OpenLab. These services and research programs operate from the PRBB building in Barcelona.

Differentiator

Problem solved

Functional benefit

Brands

• MARBiobanc: Biobank of biological samples for diagnostic and biomedical research purposes
• MARGenomics
• MARData
• MARMetabolomics
• OpenLab

Products and services

• MARGenomics Integrated service for gene expression, cytogenetic and genomic studies, part of the Scientific & Technical Services (SCT) platform offered to external researchers and institutions.
• MARBiobanc Biobank comprising collections of biological samples (tissues, sera, plasma, urine) organized as a technical unit for diagnostic and biomedical research purposes.
• MARData Umbrella entity for data science-related services operating within the Hospital del Mar Research Institute, part of Scientific & Technical Services.
• MARMetabolomics Metabolomics platform of the Hospital del Mar Research Institute in Barcelona, offering metabolomics analysis services to researchers and institutions.
• Clinical Research Unit (Unitat de Recerca Clínica) Unit accredited by the Generalitat of Catalonia as a Unit of Clinical Trials in Phase I, providing clinical research support to investigators and sponsors.
• Enzyme Immuno Assay Service Integrated sample processing service for enzyme immunoassay analysis offered through the Scientific & Technical Services platform.
• Internal Services and Cryopreservation Scientific and technical support services including cryopreservation facilities provided to research groups.
• Scientific & Technical Services (Serveis Cientificotècnics) Platform comprising multiple specialized services providing scientific and infrastructural support to researchers, including genomics, biobanking, data science, metabolomics, and clinical research services.
• Research Programme in Cancer Research programme focused on cancer studies with multiple research groups covering immunotherapy, urological cancer, colorectal cancer, hematological malignancies, and molecular targets.
• Research Programme in Neurosciences Research programme comprising 20 research groups focused on clinical research for mental and neurodegenerative illnesses, with special interest in disorders induced by psychoactive substances.
• Research Programme in Epidemiology and Public Health Research programme focused on epidemiology and public health studies.
• Research Programme in Biomedical Informatics Research programme focused on biomedical informatics and computational biology.
• Research Programme in Translational Clinical Research Translational clinical research programme comprising 12 research groups including B cell biology, heart diseases, inflammation, critical illness, hepatology, nephrology, and rehabilitation.
• OpenLab Open access research laboratory programme providing infrastructure and support for researchers.

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

15 partnerships are on record, tiered core, major and minor.

• Hospital del MarcoreStrategic or Co-development PartnerHospital del Mar Research Institute operates in close collaboration with Hospital del Mar, forming the Parc de Salut Mar. Many research groups share staff and facilities with the hospital, and clinical research is conducted jointly.
• Universitat Pompeu Fabra (UPF)coreStrategic or Co-development PartnerUPF is a key academic partner, with shared research programmes, joint seminars (HMRIB/MELIS UPF Seminar), and researchers affiliated with both institutions. The IMIM is located adjacent to UPF facilities in the PRBB.
• Universitat Autonoma de Barcelona (UAB)coreStrategic or Co-development PartnerUAB collaborates on neurosciences education and research programmes, including Master's programmes and resident doctor training. Researchers from both institutions work on joint projects.
• Parc de Recerca Biomedica de Barcelona (PRBB)coreStrategic or Co-development PartnerThe institute is housed within the PRBB building, which hosts multiple biomedical research centres. Researchers have access to shared facilities and can collaborate across institutions within the PRBB.
• Barcelona Beta Brain Research CentrecoreStrategic or Co-development PartnerCollaborates on Alzheimer's disease and neuroscience research. Dr Marc Suarez-Calvet holds dual affiliation and coordinates research groups at both institutions.
• International Stroke Genetics ConsortiummajorStrategic or Co-development PartnerAn international consortium through which HMRIB and Hospital del Mar led a study identifying genetic variants linked to complications following subarachnoid haemorrhage, published in the journal Brain.
• Biocores@BCNminorStrategic or Co-development PartnerThe Scientific-Technical Services of Hospital del Mar Research Institute are part of Biocores@BCN, a directory of basic facilities, technological platforms and scientific services in the Barcelona area.
• CERCA-GINYSminorStrategic or Co-development PartnerScientific-Technical Services are part of CERCA-GINYS, a platform providing access to scientific and technical infrastructure for the CERCA research centre community and private sector.
• CIBERFES (CIBER of Frailty and Healthy Ageing)coreStrategic or Co-development PartnerThe Musculoskeletal Research Group (GIME) is integrated into CIBERFES, a national biomedical research network focused on frailty and healthy ageing.
• RICORS (Cooperative Research Networks Oriented to Health Outcomes)coreStrategic or Co-development PartnerThe Nephropathies Research Group is part of the RICORS network in the renal area (RD24/0004/0003), integrating Spanish research in kidney disease and transplantation.
• CibernedminorStrategic or Co-development PartnerNational biomedical research network on neurodegenerative diseases that the Neurosciences Programme participates in.
• CIBEROBN (Biomedical Research Centre on Obesity and Nutrition)minorStrategic or Co-development PartnerNational research network on obesity and nutrition that some programme groups participate in.
• TESDAD (Addictions Research Network)minorStrategic or Co-development PartnerNational addiction research network that the Neurosciences Programme participates in.
• Red de Trastornos AdictivosminorStrategic or Co-development PartnerNational network on addictive disorders that the Neurosciences Programme participates in.
• ICREAcoreStrategic or Co-development PartnerICREA Research Professors including Andrea Cerutti and Damian Blasi are affiliated with the institute, bringing top-level talent through ICREA's research professorship programme.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Centro Nacional de Investigaciones Oncológicas (CNIO): CNIO is a Spanish national cancer research centre in Madrid with similar multi-group cancer research programmes and scientific-technical services — directly comparable to IMIM's Cancer Programme in scale and translational orientation.
• Centre de Regulació Genòmica (CRG): CRG is housed in the same PRBB building as IMIM and shares scientific-technical platforms and talent pools, focusing on genomics, systems biology, and cell biology — a peer in location and infrastructure rather than disease-area translational mission.
• Centro Nacional de Investigaciones Cardiovasculares (CNIC): CNIC is a Spanish national cardiovascular research centre with a comparable multi-group programme structure and translational clinical research mission, similar in size, public funding model, and disease-area depth to IMIM's cardiovascular and translational programmes.
• Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS): IDIBAPS is the biomedical research institute of Hospital Clínic de Barcelona, with a multi-programme research structure spanning cancer, neuroscience, and translational medicine — directly comparable in geographic, structural, and scientific scope to IMIM.
• Institut de Recerca Biomèdica de Lleida (IRBLleida): IRBLleida is a Catalan biomedical research institute affiliated with the Arnau de Vilanova and Santa Maria hospitals, operating within the same CERCA/ISCIII research network governance model as IMIM — a direct structural and geographic peer.
• Vall d'Hebron Institut de Recerca (VHIR): VHIR is a Barcelona-based biomedical research institute affiliated with the Vall d'Hebron University Hospital, operating a comparable portfolio of translational research programmes across multiple disease areas with shared scientific-technical platforms — making it the most direct peer to IMIM in both mission and structure.

Broad incumbents

• Institut Pasteur: Institut Pasteur is a long-established multi-programme biomedical research centre with infectious disease, neuroscience, and developmental biology programmes, operating a comparable non-profit research structure with shared scientific platforms — a much larger European incumbent with similar operational model.
• Francis Crick Institute: The Francis Crick Institute is a major UK biomedical research centre combining basic and translational science across multiple programmes with shared scientific platforms — a structural and operational peer to IMIM, but at substantially larger scale.
• Karolinska Institutet: Karolinska Institutet is a leading European medical university with extensive translational research programmes and clinical research infrastructure, comparable to IMIM's translational orientation but operating at substantially larger scale and integrated with a medical faculty.
• Max Delbrück Center for Molecular Medicine (MDC): MDC Berlin is a Helmholtz-affiliated biomedical research institute combining molecular medicine, cardiovascular, and cancer research with shared technology platforms — directly comparable in mission and platform model to IMIM, with broader scope and German federal funding base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/HMar_research
• LinkedInlinkedin.com/company/hmarresearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hospital del Mar Research Institute